학술논문

Elevated sortilin expression discriminates functional from non-functional neuroendocrine tumors and enables therapeutic targeting
Document Type
article
Source
Frontiers in Endocrinology, Vol 15 (2024)
Subject
neuroendocrine tumors
functional syndrome
carcinoid syndrome
serotonin
sortilin
organoids
Diseases of the endocrine glands. Clinical endocrinology
RC648-665
Language
English
ISSN
1664-2392
Abstract
A subset of neuroendocrine tumors (NETs) can cause an excessive secretion of hormones, neuropeptides, and biogenic amines into the bloodstream. These so-called functional NETs evoke a hormone-related disease and lead to several different syndromes, depending on the factors released. One of the most common functional syndromes, carcinoid syndrome, is characterized mainly by over-secretion of serotonin. However, what distinguishes functional from non-functional tumors on a molecular level remains unknown. Here, we demonstrate that the expression of sortilin, a widely expressed transmembrane receptor involved in intracellular protein sorting, is significantly increased in functional compared to non-functional NETs and thus can be used as a biomarker for functional NETs. Furthermore, using a cell line model of functional NETs, as well as organoids, we demonstrate that inhibition of sortilin reduces cellular serotonin concentrations and may therefore serve as a novel therapeutic target to treat patients with carcinoid syndrome.